Centene Corporation (CNC)
NYSE: CNC · Real-Time Price · USD
34.07
-0.29 (-0.84%)
At close: Oct 24, 2025, 4:00 PM EDT
34.08
+0.01 (0.03%)
After-hours: Oct 24, 2025, 7:59 PM EDT
Centene Revenue
Centene had revenue of $42.47B in the quarter ending June 30, 2025, with 16.56% growth. This brings the company's revenue in the last twelve months to $159.67B, up 10.73% year-over-year. In the year 2024, Centene had annual revenue of $147.17B with 4.09% growth.
Revenue (ttm)
$159.67B
Revenue Growth
+10.73%
P/S Ratio
0.11
Revenue / Employee
$2,639,223
Employees
60,500
Market Cap
16.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 147.17B | 5.78B | 4.09% |
| Dec 31, 2023 | 141.39B | 5.39B | 3.97% |
| Dec 31, 2022 | 136.00B | 17.43B | 14.70% |
| Dec 31, 2021 | 118.57B | 14.29B | 13.71% |
| Dec 31, 2020 | 104.28B | 33.47B | 47.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CNC News
- 14 hours ago - UnitedHealth Vs. Centene: Next Week's Q3 Earnings Should Trigger Gains For Both - Seeking Alpha
- 22 hours ago - Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning - Seeking Alpha
- 1 day ago - Centene And Oscar Health Stocks Sink After Molina Warning - Benzinga
- 2 days ago - Centene: Like ELV, Use The Panic To Buy And Forget - Seeking Alpha
- 3 days ago - Centene: High-Risk Buy With Huge Potential - Seeking Alpha
- 3 days ago - Centene: Strong Buy, For All The Wrong Reasons - Seeking Alpha
- 6 days ago - Managed Care Insurers Trading Down Ahead Of Earnings Season - Seeking Alpha
- 9 days ago - Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026 - PRNewsWire